Yingtai Medical Eyes A-Share Listing on Shenzhen ChiNext to Fund 1.8 Billion Yuan Medical Device Projects
SingTao · 1 SOURCES1 day ago2 MIN
Summary
Yingtai Medical (1501), a Hong Kong-listed medical device company, announced on Sunday that its board has approved plans for an A-share listing on the Shenzhen Stock Exchange ChiNext board. The company intends to issue up to 37.27 million A-shares with a greenshoe option for up to 42.86 million shares total, representing 16.87% of the expanded capital base. The offering proceeds of approximately 1.8 billion yuan will be directed toward medical device industrial parks, R&D projects, and marketing network development. Yingtai expects the dual Hong Kong-A share platform to provide enhanced financing flexibility and brand recognition in mainland China.
Key Points
- Yingtai Medical board approved issuing up to 37.27 million A-shares, with greenshoe option covering up to 42.86 million shares (16.87% of enlarged capital)
- Share pricing will be determined through a book-building process, with expected subscribers being independent third parties
- The Hangzhou Yingtai Innovation Medical Device Industrial Park and Yingtai Medical Innovation Medical Device Expansion project will receive over half of the 1.8 billion yuan deployment
- Remaining funds will support interventional medical device R&D, marketing network construction, working capital, and bank loan repayment
- The company stated it will self-finance any funding gap if actual net proceeds fall short of the 1.8 billion yuan project requirements
Why It Matters
The proposed A-share listing reflects a growing trend of Hong Kong-listed mainland companies seeking dual capital market presence to access deeper mainland liquidity pools. For Hong Kong investors, the move signals Yingtai's intent to expand domestic market penetration and strengthen its competitive position in China's rapidly growing medical device sector. The transaction also highlights how Hong Kong companies increasingly view the A-share market as a strategic complement to their existing equity financing platform .
The proposed A-share listing reflects a growing trend of Hong Kong-listed mainland companies seeking dual capital market presence to access deeper mainland liquidity pools. For Hong Kong investors, the move signals Yingtai's intent to expand domestic market penetration and strengthen its competitive position in China's rapidly growing medical device sector. The transaction also highlights how Hong Kong companies increasingly view the A-share market as a strategic complement to their existing equity financing platform .